Royalty Pharma plc - Class A logo

RPRX

Royalty Pharma plc - Class A

$44.09

Earnings Summary

Revenue
$535.96Mn
Net Profits
$304.5Mn
Net Profit Margins
56.82%
PE Ratio
43.06

Highlights

Revenue:

Royalty Pharma plc - Class A’s revenue fell -3.43% since last year same period to $535.96Mn in the Q2 2022. On a quarterly growth basis, Royalty Pharma plc - Class A has generated -4.64% fall in its revenue since last 3-months.

Net Profits:

Royalty Pharma plc - Class A’s net profit fell -30.92% since last year same period to $304.5Mn in the Q2 2022. On a quarterly growth basis, Royalty Pharma plc - Class A has generated 488.29% jump in its net profits since last 3-months.

Net Profit Margins:

Royalty Pharma plc - Class A’s net profit margin fell -28.47% since last year same period to 56.82% in the Q2 2022. On a quarterly growth basis, Royalty Pharma plc - Class A has generated 516.93% jump in its net profit margins since last 3-months.

PE Ratio:

Royalty Pharma plc - Class A’s price-to-earnings ratio after this Q2 2022 earnings stands at 43.06.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Royalty Pharma plc - Class A post its latest quarter earnings

EPS Estimate Current Quarter
0.78
EPS Estimate Current Year
0.78

Highlights

EPS Estimate Current Quarter:

Royalty Pharma plc - Class A’s earning per share (EPS) estimates for the current quarter stand at 0.78 - a 6.85% jump from last quarter’s estimates.

EPS Estimate Current Year:

Royalty Pharma plc - Class A’s earning per share (EPS) estimates for the current year stand at 0.78.

Key Ratios

Key ratios of the Royalty Pharma plc - Class A post its Q2 2022 earnings

Return on Assets (ROA)
0.04
Return on Equity (ROE)
0.09
Dividend Per Share (DPS)
0.72

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Royalty Pharma plc - Class A’s return on assets (ROA) stands at 0.04.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Royalty Pharma plc - Class A’s return on equity (ROE) stands at 0.09.

Dividend Per Share (DPS):

Royalty Pharma plc - Class A declared 0.72 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
0.73
0.6
-17.81%

Company Information

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma's current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates.

Organisation
Royalty Pharma plc - Class A
Headquarters
New York, New York, US
Employees
51
Industry
Health Technology